Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | CNR1 | P21554 | 7/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830574 | 0.81 | TRPV4 (0.36) | TRPV4RORCPOLBL3MBTL1HTR2A | |
| SCHEMBL5934979 | 0.81 | TRPV4 (0.38) | TRPV4CNR2CNR1RORCKAT6A | |
| SCHEMBL5831060 | 0.81 | TRPV4 (0.36) | TRPV4CNR2CNR1RORCPOLB | |
| SCHEMBL5656870 | 0.79 | KMT2A (0.40) | TRPV4CNR2CNR1POLB | |
| SCHEMBL476597 | 0.75 | CNR2 (0.46) | TRPV4CNR2CNR1RORC | |
| SCHEMBL5675120 | 0.74 | TDP1 (0.39) | TRPV4CNR2RORCCCR1 | |
| SCHEMBL15143971 | 0.72 | CNR2 (0.41) | TRPV4CNR2CNR1SLC6A3 | |
| SCHEMBL476632 | 0.72 | CNR2 (0.46) | TRPV4CNR2 | |
| SCHEMBL5660343 | 0.71 | MEN1 (0.42) | TRPV4CNR2CNR1POLB | |
| SCHEMBL3817863 | 0.71 | CNR2 (0.34) | TRPV4CNR2CNR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | claimed |
| US-7138424-B2 | Indole derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| EP-1507758-B1 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| EP-1507758-A2 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | Sanofi-Aventis (FR) | 2005-02-23 | — | — | EP | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| WO-2003097597-A2 | INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2003-11-27 | — | — | WO | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | TRPV4 193/4885CNR2 1/4885CNR1 2/4885 |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | CNR2, CNR1, IDO2 | TRPV4 208/4885CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.